Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. A chemical structure of Levetiracetam
3. Originally discovered in sound-sensitive mice
4. Antiepileptic drug discovery
5. Inactivity in MES and s.c. PTZ seizure tests
6. Levetiracetam in electroshock and PTZ seizures
7. Protection against seizures in rat model
8. Levetiracetam activity in GAERS model
9. High therapeutic index of Levetiracetam
10. No negative impact on cognitive function (1)
11. No negative impact on cognitive function (2)
12. Hyper-synchronization/excitability inhibition in vitro
13. Levetiracetam inhibits hyper-synchronization
14. Effect on development of amygdala kindling
15. Effect on seizures in genetic models of epilepsy
16. Chemical structure and pharmacological profile
17. Mechanisms targeted in AED discovery (1)
18. Inactivation of sodium channels
19. Reduction of current through T-type Ca channels
20. No conventional GABAergic effects
21. Mechanisms targeted in AED discovery (2)
22. Levetiracetam mechanism of action (1)
23. Levetiracetam mechanism of action (2)
24. Levetiracetam binding site - novel radioligand
25. Levetiracetam binding site - characteristics
26. SV2 proteins: candidates for the LEV binding site
27. SV2 proteins knockout studies
28. SV2A cloning and binding studies
29. Affinities for hSV2A and anti-seizure potencies
30. SV2A - novel intracellular and presynaptic target
31. SV2A - broad-spectrum anticonvulsant target
32. Kindling acquisition in SV2A (+/-) mice
33. Levetiracetam studies in SV2A (+/-) mice (1)
34. Levetiracetam studies in SV2A (+/-) mice (2)
35. Target validation of SV2A
36. Profile of new class of antiepileptic drugs

Topics Covered

• Levetiracetam
• Antiepileptic Drug Discovery
• Levetiracetam in electroshock and PTZ seizures
• Protection against seizures in rat model
• Levetiracetam activity in GAERS model
• Impact on cognitive function
• Hyper-synchronization / excitability inhibition in vitro
• Effect on development of amygdala kindling
• Effect on seizures in genetic models of epilepsy
• Inactivation of sodium channels
• Reduction of current through T-type Ca channels
• Levetiracetam mechanism of action
• SV2 proteins: candidates for the LEV binding site
• SV2A cloning and binding studies
• Levetiracetam studies in SV2A (+/-) mice
• Profile of new class of antiepileptic drugs

Links

Series:

• Drug Discovery and Development in the Neurosciences
• Small Molecule Drug Discovery

Categories:

• Biochemistry
• Cell Biology
• Diseases, Disorders & Treatments
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Klitgaard, H. (2013, March 28). Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 23, 2020, from https://hstalks.com/bs/2524/.

Publication History

• Published on March 28, 2013

Financial Disclosures

• Dr. Henrik Klitgaard has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.